CureVac (CDMO Services)

Tubingen, DE
Hybrid — also manufactures internal programs
mRNA
4 confirmed programs · 1 sponsors · Last scored 2026-04-02
75.3
Signal Score
○ FDA Inspections ✓ Clinical Trials (4) ○ SEC Filings ○ Press ✓ EMA GMP (4) ○ MHRA GMP

Quick Facts: CureVac (CDMO Services)

Signal Score
75.3/100 (as of 2026-04-02)
Quality Compliance
100.0/100 — No FDA inspection records found for this manufacturer
Headquarters
Tubingen, DE
Modalities
mRNA
Active Programs
4 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
EMA GMP Certificates4 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 52.5
4 active programs across 1 sponsors
Modalities: mRNA
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
4 active programs across 1 sponsors · Modalities: mRNA · 1 programs in advanced phases (Phase 2/3)
Programs 4
Sponsors1
ModalitiesmRNA
4 active programs across 1 sponsors
Modalities: mRNA
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07073183 Safety and Tolerability of CVHNLC Plus Pembrolizumab in... PHASE1 Not Yet Recruiting
NCT03291002 Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC PHASE1 Unknown
NCT01915524 Trial of RNActive®-Derived Cancer Vaccine and Local Radiation... PHASE1 Terminated
NCT00923312 Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV... PHASE1/PHASE2 Completed
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability 83.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity 53.0
1 manufacturing site: Tubingen, Germany
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: Tubingen, Germany
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Tubingen, Germany
Modalities: mRNA
Capacity assessment: 53.0/100

EMA GMP Compliance 4 certificates

2024-12
2023-09
2023-09
2023-05
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
DE_BW_01_GMP_2025_0094 CureVac Manufacturing GmbH Germany 2024-12-17 COMPLIANT
DE_BW_01_GMP_2024_0013 CureVac Manufacturing GmbH Germany 2023-09-28 COMPLIANT
DE_BW_01_GMP_2024_0012 CureVac Manufacturing GmbH Germany 2023-09-28 COMPLIANT
DE_BW_01_GMP_2023_0203 CureVac RNA Printer GmbH Germany 2023-05-23 COMPLIANT
Source: EMA EudraGMDP · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →

Similar CDMOs

BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
Signal Score: 84.8
mRNA
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.8
mRNA, Biologics, Cell Therapy
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Signal Score: 81.6
mRNA, Plasmid, Biologics
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 81.6
mRNA, Oligonucleotide, Biologics
Ethris
Planegg, DE
Signal Score: 56.5
mRNA